No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 173 | 194 | 207 | 252 | 244 | 252 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 13 | -1 | -10 | -4 | 8 | 10 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and effervescent powders and granules. These nutraceutical products are designed to support a wide range of health needs, encompassing areas like probiotics, multivitamins and minerals, immune system function, sleep and relaxation, gastrointestinal and circulatory health, osteoarticular and urinary systems, women's health, beauty, healthy aging, and mental wellbeing. In addition to its core CDMO services, the company also manufactures and sells a diverse array of cosmetic products, covering hair care, skin care, liquid personal hygiene items, oral hygiene products, deodorants, alcohol-based perfumery, bath and shower gels, shampoos and conditioners, shaping waxes, mouthwashes, creams, gels, and toothpastes. Furthermore, they supply medical surgical aids and devices, various antiseptics for intact skin, hand sanitizers, pre-injection solutions, hydroalcoholic surface cleaners, and iodine. Their product line also extends to orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. Established in 1984, the company is headquartered in Verdellino, Italy.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. (FF.MI)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and effervescent powders and granules. These nutraceutical products are designed to support a wide range of health needs, encompassing areas like probiotics, multivitamins and minerals, immune system function, sleep and relaxation, gastrointestinal and circulatory health, osteoarticular and urinary systems, women's health, beauty, healthy aging, and mental wellbeing. In addition to its core CDMO services, the company also manufactures and sells a diverse array of cosmetic products, covering hair care, skin care, liquid personal hygiene items, oral hygiene products, deodorants, alcohol-based perfumery, bath and shower gels, shampoos and conditioners, shaping waxes, mouthwashes, creams, gels, and toothpastes. Furthermore, they supply medical surgical aids and devices, various antiseptics for intact skin, hand sanitizers, pre-injection solutions, hydroalcoholic surface cleaners, and iodine. Their product line also extends to orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. Established in 1984, the company is headquartered in Verdellino, Italy.
